A P-type dopant is provided, which is a planar aromatic compound having different numbers of fluorine atoms and cyano groups connected at a periphery thereof, and allows adjustment of highest occupied molecular orbital (HOMO) energy levels and lowest unoccupied molecular orbital (LUMO) energy levels and effectively increases luminous efficiency of a light emitting layer. Moreover, an organic light emitting diode is disclosed, including an anode, a cathode, and a light emitting structure located between the anode and the cathode, wherein a hole injecting layer of the light emitting structure is a hole injecting layer including the P-type dopant described above.

A process of preparing 2-cyclohexyliden-2-phenyl acetonitrile or odoriferous structural analogs thereof, represented by Formula I:

##STR00001##

wherein the variables are as defined in the specification, is provided. The process utilizes a phase transfer catalyst, is performed at a temperature lower than 80 C., and provides odoriferous substances at a high yield and purity. Odoriferous substances obtainable by the process, and odor-imparting formulations and articles-of-manufacturing containing same are also provided

A process of preparing 2-cyclohexyliden-2-phenyl acetonitrile or odoriferous structural analogs thereof, represented by Formula I:

##STR00001##

wherein the variables are as defined in the specification, is provided. The process utilizes a phase transfer catalyst, is performed at a temperature lower than 80 C., and provides odoriferous substances at a high yield and purity. Odoriferous substances obtainable by the process, and odor-imparting formulations and articles-of-manufacturing containing same are also provided

Provided is a compound of Chemical Formula 1:

##STR00001##

where R.sub.1 and R.sub.2 are each independently hydrogen, a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, tri(C.sub.1-60 alkyl)silyl, a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing at least one of O, N, Si and S,

R.sub.3 and R.sub.4 are each independently hydrogen, deuterium, a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, tri(C.sub.1-60 alkyl)silyl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing at least one of O, N, Si and S, and

Ar is C.sub.6-60 aryl, or C.sub.2-60 heteroaryl containing at least one of O, N, Si and S, wherein the C.sub.6-60 aryl, or C.sub.2-60 heteroaryl is substituted with 1 to 5 substituents each selected from the group consisting of a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, and tri(C.sub.1-60 alkyl)silyl,

and an organic light emitting device including the same.

Compounds of the general formula): ##STR00001##
processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

A reconfigurable polar molecule includes a symmetric nonpolar molecule portion having an elongated shape defined by a longitudinal axis and lateral axis, the longitudinal axis being longer than the lateral axis; a positive ionically charged group at a first end and a negative ionically charged group at a second end of the longitudinal axis, the positive and negative ionically charged groups forming a permanent dipole; a first bridging group and a second bridging group on opposing ends of the lateral axis, the first and second bridging groups being linear nonpolar groups; and a first support portion bonded to the first bridging group, and a second support portion bonded to the second bridging group, the first bridging group and the second bridging group being nonpolar and having structures that enable free rotation of the symmetric nonpolar molecule portion through the first bridging group and the second bridging group.

A reconfigurable polar molecule includes a symmetric nonpolar molecule portion having an elongated shape defined by a longitudinal axis and lateral axis, the longitudinal axis being longer than the lateral axis; a positive ionically charged group at a first end and a negative ionically charged group at a second end of the longitudinal axis, the positive and negative ionically charged groups forming a permanent dipole; a first bridging group and a second bridging group on opposing ends of the lateral axis, the first and second bridging groups being linear nonpolar groups; and a first support portion bonded to the first bridging group, and a second support portion bonded to the second bridging group, the first bridging group and the second bridging group being nonpolar and having structures that enable free rotation of the symmetric nonpolar molecule portion through the first bridging group and the second bridging group.

The present invention refers to a process for a Rh-catalyzed Anti-Markovnikov hydrocyanation of terminal alkynes which process discloses, for the first time, the highly stereo- and regio-selective hydrocyanation of terminal alkynes to furnish E-configured alkenyl nitriles and the catalyst used in the present process.

The present invention refers to a process for a Rh-catalyzed Anti-Markovnikov hydrocyanation of terminal alkynes which process discloses, for the first time, the highly stereo- and regio-selective hydrocyanation of terminal alkynes to furnish E-configured alkenyl nitriles and the catalyst used in the present process.

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.